Comparative Pharmacology
Head-to-head clinical analysis: LIALDA versus SFROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIALDA versus SFROWASA.
LIALDA vs SFROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mesalamine, the active ingredient in Lialda, is an anti-inflammatory agent that inhibits prostaglandin production and leukotriene synthesis, and reduces cytokine production in the colonic mucosa.
SFROWASA is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
2-4 tablets (2.4-4.8 g) orally once daily. Each tablet contains 1.2 g mesalamine.
5-aminosalicylic acid (mesalamine) 1 g orally 4 times daily for acute treatment; maintenance 500 mg orally 3 times daily.
None Documented
None Documented
Terminal elimination half-life of mesalamine is approximately 12 hours (range 8-15 hours) for the sustained-release formulation; clinical steady-state is reached within 3-5 days.
Terminal elimination half-life: 12-14 hours in healthy adults; prolonged in hepatic impairment (up to 24 hours) or severe renal disease (up to 20 hours).
Renal (primarily, as N-acetyl-5-aminosalicylic acid, about 80%) and fecal (as unchanged mesalamine, about 20%).
Renal: 80% as unchanged drug; biliary/fecal: <15% as metabolites; minor hepatic metabolism via CYP3A4.
Category C
Category C
Aminosalicylate
Aminosalicylate